A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Pfizer
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Pheon Therapeutics
Kestrel Therapeutics, Inc.
Revolution Medicines, Inc.
Seagen Inc.
Alterome Therapeutics, Inc.
Orano Med LLC
RasCal Therapeutics, Inc.
Pfizer
Xencor, Inc.
Mirati Therapeutics Inc.
National Institutes of Health Clinical Center (CC)
Pheon Therapeutics
City of Hope Medical Center
Novartis
AstraZeneca
Chongqing Precision Biotech Co., Ltd
HUYABIO International, LLC.
HUYABIO International, LLC.
Elicio Therapeutics
Revolution Medicines, Inc.
GONGCHU Biotechnology Co., Ltd
Novita Pharmaceuticals, Inc.
Compugen Ltd
Columbia University
Black Diamond Therapeutics, Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Sichuan University
Compugen Ltd
Mirati Therapeutics Inc.
Second Affiliated Hospital of Guangzhou Medical University
ADC Therapeutics S.A.
HiberCell, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Lebanese University
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Provectus Pharmaceuticals
Novartis
MacroGenics
MacroGenics